In line with the in vitro colony formation assays described above, YAP/TAZ deficiency resulted in an increased sensitivity to Sorafenib treatment in vivo, as reflected by decreased tumor growth rates as well as by smaller tumor masses at end point analysis (Fig 6B–D). Here, YAP1 is linked to neoplasm.